1 Disability-adjusted life years (DALYs) due to the direct health impact of COVID-19 in

- 2 India, 2020
- 3 Balbir B Singh^{a,b,c}, Brecht Devleesschauwer^{d,e}, Mehar S Khatkar^b, Mark Lowerison^{f,g}, Baljit
- 4 Singh^{f,h}, Navneet K Dhand^b and Herman W Barkema^{f,g,i}
- ^aCentre for One Health, Guru Angad Dev Veterinary and Animal Sciences University,
- 6 Ludhiana, Punjab 141004, India
- ^bSydney School of Veterinary Science, The University of Sydney, 425 Werombi Road,
- 8 Camden, 2570 NSW, Australia
- ⁹ ^cDept. of Veterinary Microbiology, University of Saskatchewan, Saskatoon, Canada
- ^dDepartment of Epidemiology and Public Health, Sciensano, Rue Juliette Wytsman 14,
- 11 BE-1050, Brussels, Belgium
- ^eDepartment of Veterinary Public Health and Food Safety, Ghent University,
- 13 Salisburylaan 133, BE-9820, Merelbeke, Belgium
- ¹⁴ ¹⁴ ¹⁴ Dept. of Community Health Sciences, Cumming School of Medicine, University of
- 15 Calgary, 3330 Hospital Drive NW, Calgary, AB, Canada, T2N 4N1
- ^gOne Health at UCalgary, University of Calgary, 3330 Hospital Drive NW, Calgary,
- 17 Canada, T2N 4N1
- ¹⁸ ^hUniversity of Saskatchewan, Saskatoon, SK, Canada
- ¹⁹ ¹Dept. of Production Animal Health, Faculty of Veterinary Medicine, University of
- 20 Calgary, 3330 Hospital Drive NW, Calgary, Canada, T2N 4N1
- 21 **Corresponding author:**
- 22 Balbir B Singh, Professor, Centre for One Health, Guru Angad Dev Veterinary and
- 23 Animal Sciences University, Ludhiana, Punjab 141004, India
- 24 Email: bbsdhaliwal@gmail.com; Tel.: +91 161 2414009; Fax: +91 161 2400822
- 25

26 Abstract

27	COVID-19 has affected all countries. Its containment represents a unique challenge for India
28	due to a large population (>1.38 billion) across a wide range of population densities.
29	Assessment of the COVID-19 disease burden is required to put the disease impact into
30	context and support future pandemic policy development. Here, we present the national-level
31	burden of COVID-19 in India in 2020 that accounts for differences across urban and rural
32	regions and across age groups. Disability-adjusted life years (DALY) due to COVID-19 were
33	estimated in the Indian population in 2020, comprised of years of life lost (YLL) and years
34	lived with disability (YLD). Scenario analyses were conducted to account for excess deaths
35	not recorded in the official data and for reported COVID-19 deaths. The direct impact of
36	COVID-19 in 2020 in India was responsible for 14,106,060 (95% uncertainty interval [UI]
37	14,030,129–14,213,231) DALYs, consisting of 99.2% (95% UI 98.47–99.64%) YLLs and
38	0.80% (95% UI 0.36–1.53) YLDs. DALYs were higher in urban (56%; 95% UI 56–57%)
39	than rural areas (44%; 95% UI 43.4–43.6) and in males (64%) than females (36%). In
40	absolute terms, the highest DALYs occurred in the 51-60-year-old age group (28%) but the
41	highest DALYs per 100,000 persons were estimated for the 71-80 year old age group (5,481;
42	95% UI 5,464–5,500 years). There were 4,823,791 (95% UI 4,760,908–4,924,307) DALYs
43	after considering reported COVID-19 deaths only. The DALY estimations have direct and
44	immediate implications not only for public policy in India, but also internationally given that
45	India represents one sixth of the world's population.
46	

47 Keywords: COVID-19; Disability-adjusted life years; India; Years lived with disability;
48 Years of life lost

49 **1.0 Introduction**

50	The coronavirus disease 2019 (COVID-19) pandemic ¹ originated in Wuhan, China in
51	December 2019 ² and eventually worldwide. The disease is caused by the severe acute
52	respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that infects humans ³ . As of 30 July
53	2021, 196,553,009 cumulative cases and 4,200,412 cumulative deaths have been reported
54	worldwide ⁴ . The virus spreads via respiratory droplets, and aerosols shed from infected
55	individuals ^{5,6} or directly through contaminated hands ⁷ . Important symptoms include fever,
56	respiratory tract symptoms such as cough, pneumonia, shortness of breath and can progress to
57	serious illness and even death ^{8,9} . In addition, long or post-acute COVID-19 syndrome with
58	symptoms and abnormalities after 12 weeks following the onset of acute COVID-19
59	infections has also been recognised ¹⁰ .
60	The first case of COVID-19 in India was reported on 30 January 2020. The government of
61	India implemented staged lockdowns and intense contact mitigation to overcome this
62	challenge; however, these interventions were only able to slow but did not halt the spread of
63	COVID-19 in India ¹¹ . As of 30 July 2021, 31,572,344 cumulative cases and 423,217
64	cumulative deaths have been reported in India ⁴ . The adjusted case fatality risk (aCFR) due to
65	COVID-19 in India has been reported to be 1.4 and 3.0% using random- and fixed-effects
66	models, respectively ¹² . At the end of the first wave (15 February 2021), the cumulative aCFR
67	declined to 1.2% using random and 1.6% using fixed-effects models ¹² . The aCFR in India
68	was associated with co-morbidities such as the incidence of diabetes, cardiovascular diseases,
69	hypertension, and acute respiratory infections ¹² .
70	The health impact of COVID-19 is being investigated across the globe. A recent study
71	reported 1,279,866 deaths due to COVID-19 in 81 countries with an average of 16 years of

 72 life lost (YLL) per death resulting in 20,507,518 YLL 13 . In the Kerala state of India, 709.2

73 DALYs per 100,000 population have been estimated from the inception of the pandemic to

74	20 August 2020 ¹⁴ . However, despite being the second most populous country in the world,
75	no comprehensive assessment of the disease burden of COVID-19 in India has been
76	undertaken. In this study, we estimated DALYs due to the direct health impact of COVID-19
77	in India from 30 January 2020 (the first case reported) to 31 December 2020. Domain,
78	gender, and age-specific DALY estimates are provided to understand health impacts of
79	COVID-19 in India.
80	2.0 Methods
81	2.1 COVID-19 case and death data
82	The COVID-19 cumulative case and death data till 31 December 2020 were extracted using
83	the Government of India Ministry of Health and Family Welfare (MoHFW) COVID-19
84	tracker on 18 January 2021, 8:00 AM ¹⁵ . Age-, gender- and domain-specific distributions of
85	COVID-19 cases as provided by the National Centre for Disease Control, Government of
86	India (as of 18 January 2021) were used in the analysis ¹⁶ . The National Centre for Disease
87	Control data on the proportion of deaths in various age groups as of 2 September 2020 were
88	recorded from the published literature ¹⁷ . Gender-specific mortality risk (64% in males and
89	36% in females) reported by the MoHFW were also recorded as of 21 May 2020 ¹⁸ . Domain-
90	specific COVID-19 death data (rural vs urban) were obtained from the news item published
91	online (https://www.downtoearth.org.in/news/health/more-than-half-of-india-s-april-covid-
92	19-deaths-were-in-rural-districts-76782) indicating 56% deaths in urban and 44% deaths in
93	rural districts during March 2020-April 2021.
94	Several studies indicate 48.5% 19 , 52.5% 20 , and 57.8% 21 of SARS-CoV-2 infected
95	individuals remained asymptomatic in the country. A systematic review and meta-analysis
96	conducted using the studies conducted worldwide till 10 June 2020 indicated 31% (95% CI
97	26–37%) of infected people to be asymptomatic 22 . Based on all these studies, we assumed
98	that 31–57.8% of infected people to be asymptomatic in the country.

99	As of 17 July 2020, the MoHFW reported that there were 2.8% cases on oxygen beds, 1.9%
100	cases in intensive care units (ICUs), and 0.35% cases on ventilators 23 . As of September 4,
101	2020, the MoHFW reported updated estimates of 3.5% cases on oxygen beds, 2.0% cases in
102	ICUs, and 0.50% cases on ventilators ²³ . Based on both estimates, we assumed 4.8-5.5% of
103	severe (patients in ICU plus those needing oxygen support), and 0.35-0.5% of critical
104	(patients on ventilators) cases in the country. The proportion of cases that were not
105	asymptomatic, severe or critical were assumed to be mild/moderate cases.
106	No data were available for the proportion of cases having post-acute COVID-19 syndrome
107	(PCS) from India. A UK COVID symptom study indicates that approximately 10% of
108	COVID-19 patients suffer from PCS ^{24,25} . Other studies report that 51% of the patients in
109	Spain ²⁶ and 32.5% of patients in the United states ²⁷ suffer from PCS. Based on the above-
110	mentioned findings, we assumed that 32.5% of the mild/moderate, severe or critical cases
111	would suffer from PCS in India. Details of COVID-19 cases and death input data have been
112	presented in Table S1.
113	2.2 COVID-19 severity data
114	COVID-19 outcomes model and value of health loss as described by Wyper, et al. ²⁸ were
115	used in the current estimations ^{29,30} . For COVID-19 infections, disability weight(s) of 0.051
116	(0.032-0.074) for mild/moderate, 0.133 (0.088-0.190) for severe, 0.655 (0.579-0.727) for
117	critical, and 0.219 (0.148-0.308) for post-acute consequences cases were used. Per definition,
118	the disability weight for asymptomatic cases equaled zero.
119	A mean duration of 7.79 days (6.20 - 9.64 days) has been estimated using meta-analysis for

- 120 lower respiratory infections (LRI)³¹. A study from India reported the interval to resolution of
- 121 COVID-19 symptoms to be a median of 7.0 days (2.0-9.5 days)³². Similarly, another study
- reported a median moderate COVID-19 duration of 6.0 days (3-11 days)³³. Based on all

these estimates, we used a median of 7 days (2-11 days) as the disease duration for

- 124 mild/moderate COVID-19 in India.
- 125 A study from India reported 12 days duration of COVID-19 for hospitalized patients 34 .
- 126 Another study from Germany also reported an overall hospitalization of 12 (7–20) days for
- 127 COVID-19 patients needing oxygen supplementation outside the ICU³⁵. For critical patients,
- duration in the ICU for 9 (7-11) days has been reported 36 . A Belgian study reported the time
- between symptom onset and hospitalization to vary from 3-10.4 days ³⁷. Therefore, we used
- 130 18 (10-30.4) days as the disease duration for severe and critical COVID-19 (symptom onset
- 131 to hospitalization duration plus hospitalization duration) in India.
- 132 A recent review on PCS indicated the duration of PCS in various countries varied from 1 to 6
- 133 months post-symptom onset, with a 2-month duration commonly reported 10 . Therefore, we
- used a median of 60 days (30 180 days) as the disease duration for PCS in India. Details of
- 135 COVID-19 severity-related input data have been presented in Table S1.

136 <u>2.3 Demographic data</u>

137 The human population in India for 2020 was projected to be 1,380,004,390³⁸. However, age-,

138 domain- and gender-specific proportions of the population were not available for the year

139 2020. Therefore, we used the age-, domain- and gender-specific proportion of the population

- 140 from the 2011 human population census data ³⁹ assuming it to be constant for 2011 and 2020
- 141 population data. Life expectancy was derived as per the standard life expectancy table of
- 142 Global Burden of Disease Study 2019⁴⁰. Details of demographic data have been presented in
- Table S1.

144 <u>2.4 COVID-19 deaths</u>

145 Excess deaths due to COVID-19 in India for the year 2020 were estimated (Table S1) using

146 COVID-19 mortality estimates from March 2020 to May 2021 generated by the Institute for

147 Health Metrics and Evaluation, Washington ⁴¹. Using the IHME data, the confidence interval

148 of the proportion of the reported COVID-19 deaths to the excess deaths was estimated 42 . We

- assumed that there will be a similar proportion of excess deaths during the year 2020 as
- reported from March 2020 to May 2021. As age, domain, and gender-specific proportion of
- 151 excess deaths were unavailable, we assumed that the proportion of excess deaths will be
- similar to those reported for COVID-19 deaths.
- 153 <u>2.5 Calculation of disability-adjusted life years</u>
- 154 DALYs were estimated as the sum of YLDs and YLLs. YLL was estimated by multiplying
- the number of deaths due to COVID-19 by the residual standard life expectancy at the age of
- 156 death due to the disease. YLD was calculated as a product of the number of incident cases of
- 157 COVID-19, disease duration and disability weight. Domain-, gender- and age-specific
- 158 DALYs were estimated as per Devleesschauwer et al. 2014a and 2014b ^{43,44}. We assumed
- that cases were sick before dying; therefore, both YLDs and YLLs were estimated for
- 160 COVID-19 deaths.
- 161 Scenario analyses were conducted using a) excess COVID-19 deaths reported by IHME 41 ,
- and b) officially reported deaths ¹⁵ to estimate DALYs associated with COVID-19 in India.
- 163 Uncertainty was propagated using 10,000 Monte Carlo simulations. Uniform probability
- distributions were applied for the proportion of patients having mild/moderate, severe, or
- 165 critical symptoms. Triangular distribution(s) were applied to disability weights and COVID-
- 166 19 disease duration associated with various COVID-19 outcomes. A triangular distribution
- 167 was also applied to excess COVID-19 deaths during the calendar year 2020.
- 168 The resulting uncertainty distributions were summarized by their mean and a 95% uncertainty
- 169 interval (UI) defined as the distribution's 2.5th and 97.5th percentile.
- 170 All analyses were conducted using R version 3.6.3 (R Development Core Team,
- 171 <u>http://www.r-project.org</u>).

172

173 **3.0 Results**

174 <u>3.1 Disability-adjusted life years</u>

- 175 The direct impact of COVID-19 was responsible for 14,106,060 DALYs consisting of
- 176 13,992,803 (99.2%; 95% UI 98.47–99.64%) YLLs and 113,257 (0.80%; 95% UI 0.36–
- 177 1.53%) YLDs in 2020 in India (Table 1). There were 7,970,337 DALYs in urban (56%) as
- compared to 6,135,722 in rural (44%) areas (Table 1). There were 9,028,492 DALYs in
- males (64.0%) as compared to 5,077,568 DALYs in females (36.0%) (Table 1). The highest
- 180 DALYs were reported in persons 51-60 years (3,922,508; 28%, Table 2). Mortality
- 181 contributed towards almost all (99.2%) DALYs due to the direct impact of COVID-19 in
- 182 India. There were 31.67 YLLs per COVID-19 death in the country. PCS contributed towards
- 183 89.61% (95% UI 79.1–95.62%) of the YLDs.
- 184 <u>3.2 Disability-adjusted life years per 100,000 people</u>
- 185 There were 1,022 DALYs, 1,014 YLLs, and 8 median YLDs per 100,000 persons per year in
- the country (Table 1). The median DALYs per 100,000 persons per year were higher in urban
- as compared to rural (1,854 vs 646) and in males as compared to females (1,270 vs 758) in
- 188 India. The highest DALYs per 100,000 persons per year were at 5,481 (95% UI 5,464–5,500)
- reported in persons belonging to the age group of 71-80 years in India (Table 2).
- 190 <u>3.3 Scenario analyses</u>
- 191 The DALYs, YLLs and YLDs were approximately 3 times lower after considering reported
- 192 COVID-19 deaths only (Table S2). There were 4,823,791 DALYs, 4,710,106 YLLs and
- 193 113,685 YLDs due to reported COVID-19 deaths. There were 349 DALYs, 341 YLLs and 8
- 194 YLDs per 100,000 persons per year due to reported COVID-19 deaths in the country (Table
- 195 S2). A proportional decrease in age-wise DALYs and YLLs after excluding excess COVID-
- 196 19 deaths is also presented in Table S3.

197

We estimated DALYs due to the direct impact of COVID-19 in 2020 in India. Furthermore,

198 **4.0 Discussion**

199

200 we also accounted for excess COVID-19 deaths (not officially reported) for accurate DALY 201 estimates. As far as we are aware, DALY estimations for COVID-19 for the full 2020 year 202 have not been reported from India. Therefore, the current study will provide valuable insights 203 into health impacts of COVID-19 in 2020 in India. 204 We believe IHME excess COVID-19 deaths prediction to be accurate, as it was based on 205 models using week-by-week measurements of excess death rate during the ongoing COVID-206 19 pandemic. Furthermore, 6 drivers of all-cause mortality, including: a) the excess COVID-207 19 death rate, b) excess mortality due to delayed or deferred health care, c) excess mortality 208 due to mental health disorders, d) reductions in mortality due to decrease in injuries, e) 209 decrease in mortality due to other viruses, and f) and decrease in mortality due to certain 210 chronic conditions, were also taken into account to accurately predict excess COVID-19 211 deaths nationally and various regions globally⁴¹. 212 There was a loss of 1,022 healthy years of life per 100,000 person-years and 14 million 213 DALYs due to the direct impact of COVID-19 in 2020 in India. In 2019, there were overall 468 million DALYs in India ⁴⁵ indicating that the DALYs due to COVID-19 could account 214 215 for almost 3% of the total DALYs in India. In 2017, the top 15 causes of DALYs per 1,000 216 person-years in India ranges from ischaemic heart disease (35.0) to fever of unknown origin (9.0)⁴⁶. Therefore, if excess deaths due to COVID-19 were accounted, the direct impact of 217 218 COVID-19 would be among the top 15 causes but not among the top 10 of DALYs in 2020 in 219 India. These estimates of direct impact of COVID-19 are lower than ischaemic heart disease, 220 nutritional deficiencies, chronic respiratory diseases, neuropsychiatric conditions, diarrhoea, 221 vision and other sensory loss, respiratory infections, cancers, stroke, road traffic accidents,

tuberculosis, liver and alcohol-related conditions, but higher than musculoskeletal disorders

and fever of unknown origin.

224	There are considerable variations among countries in estimated DALYs. For example, there
225	were 1,767–1,981 DALYs per 100,000 person-years due to COVID-19 during 2020 in
226	Scotland ⁴⁷ , 4.9 (20 January to 24 April 2020) in Korea ⁴⁸ , and 368 in Germany in 2020 ⁴⁹ .
227	There were 1200 YLLs per 100,000 capita during the first year of the pandemic in USA 50 .
228	Based on the reported COVID-19 death data, the DALYs per 100,000 person-years were
229	approximately similar to those reported for Germany. However, after accounting for excess
230	COVID-19 deaths, the DALYs per 100,000 person-years were much closer to those reported
231	from the USA.
232	Median DALYs were higher in urban areas (56%) compared to rural areas. Similarly, urban-
233	rural differences in exposures and outcomes of COVID-19 have been reported in the USA ⁵¹ .
234	This is because a high number of cases and deaths were reported from urban as compared to
235	rural areas. Perhaps contact patterns are different in urban areas and rural areas. For example,
236	a social contact rate of 17.0 in rural ⁵² , 28.3 in urban developed centres and 67.4 in urban
237	slum areas ⁵³ per person per day was recorded in various domains in India.
238	Median DALYs were higher in males (64.0%) as compared to females (36.0%). Similar
239	trends have been observed globally. Out of 121,449 DALYs in Italy, 82,020 were in males
240	and 39,429 in females ⁵⁴ . Higher YLLs have been reported in males in 30 high incidence
241	countries ⁵⁵ . Gender-specific DALY differences are due to a difference in proportion in cases
242	and deaths among males and females. Furthermore, women have fewer contacts than men
243	outside the home ⁵² . In addition, being a male has been identified as a risk factor for death
244	and ICU admission due to COVID-19 ⁵⁶ .
245	Mortality contributed (99.61%) towards almost all the DALYs due to the direct impact of

246 COVID-19 in India, in line with other studies ^{49,54,57}. There was a median of 31.67 YLLs per

247	COVID-19 death in India. This is because highest median YLLs were estimated for the
248	population in the 51-60 year (3,906,065) and 61-70 year (3,256,690) age-groups,
249	respectively. A study from two Indian states also reported that cases and deaths are
250	concentrated in younger cohorts in the country as compared to high-income countries ⁵⁸ . Our
251	DALY estimations were derived using the standard life expectancy table of Global Burden of
252	Disease Study 2019 ⁴⁰ . In Germany, 9.6 YLL per death have been reported; however, a
253	higher YLL per death of 25.2 have been reported for persons under 70 years of age ⁴⁹ . YLL
254	per COVID-19 death ranged from 15.3 to 15.5 in Scotland ⁵⁹ . However, these estimates could
255	not be compared due to different life expectancy tables used in the analysis.
256	There are uncertainties surrounding these estimates. Undercounting or underreporting of
257	COVID-19 cases and deaths is a serious concern and is more relevant in low- and middle-
258	income countries such as India 60. We used IHME excess COVID-19 deaths and officially
259	reported data to drive our estimates. As exact data on the total number of deaths during 2020
260	remain unavailable (India's Civil Registration System data), DALYs after accounting for the
261	exact number of excess deaths could not be estimated. Grey literature indicates that there
262	were 13,297 more deaths during March-September 2020 as compared to the same period in
263	2019 and 14,944 as compared in 2018 in Mumbai, India
264	(https://timesofindia.indiatimes.com/city/mumbai/13k-more-deaths-in-city-this-year-
265	between-march-sept/articleshow/78920631.cms). Conversely, the Kerala state of India
266	reported an 11.1% reduction in all-cause mortality during 2020 as compared to 2019 ⁶¹
267	possibly due to high reduction in other cause mortality as compared to COVID-19 associated
268	excess mortality. Globally, comparative analyses using COVID-19 attributable and excess
269	death approaches indicate that YLL estimations using attributable deaths maybe 3 times
270	lower than those accounting for excess deaths; however, these estimates maybe even 12 times
271	lower in some countries ¹³ . To overcome this issue, we used excess mortality due to COVID-

272	19 from March	2020 to May 20	021 as estimated by	y the IHME.	Washington ⁴	¹ . In addition, no

- 273 data were available on age- and domain-specific proportions of excess deaths. We assumed
- this proportion to be similar to reported deaths. Therefore, the availability of all-cause
- 275 mortality data in future will further refine COVID-19 associated DALY estimations in India.
- Furthermore, no data were available on the proportion of post-acute covid manifestations and
- 277 was derived from other studies. This might have resulted in over or under estimation in the
- 278 presented DALY. Lastly, indirect impact of COVID-19 especially due to disruption of health
- 279 services could not be estimated.
- 280 Overall, direct impact of COVID-19 could be among the top 15 causes of DALYs in India.
- However, the estimated impact of COVID-19 would be substantially higher if indirect
- impacts of COVID-19 were to be accounted. Health impacts of COVID-19 varies in
- substantially in urban and rural areas. The current study will help to understand health
- impacts of COVID-19 in India and in other regions and countries.

285 ACKNOWLEDGEMENTS

- 286 The authors acknowledge India's National and State Health departments for collecting daily
- 287 COVID-19 epidemic data and releasing it in the public domain.

288 CONFLICT OF INTEREST

289 The authors declare no conflicts of interest.

290 ETHICAL STATEMENT

- 291 Informed consent for collection of epidemiological data was not required, as these data were
- already coded and available in the public domain. No identifiable personal information was
- used in this study.

294 AUTHOR CONTRIBUTORS

- BBS conceived the study. NKD, MSK and BD contributed to the conceptual model
- development. BBS build the model and conducted the analyses. BBS prepared the first draft

- 297 of the paper which was reviewed and edited by NKD, MSK, HWB, ML, BS and BD. HWB
- and NKD coordinated the project and preparation of the manuscript.

299 **ORCID**

- 300 Balbir B Singh (0000-0002-6823-6146)
- 301 Herman W Barkema (0000-0002-9678-8378)
- 302 Navneet Dhand (0000-0002-4362-3596)
- 303 Brecht Devleesschauwer (0000-0002-2867-6892)
- 304 Mehar Khatkar (0000-0002-4554-1404)

305 DATA AVAILABILITY STATEMENT

- 306 The analysed data are available along with the manuscript. Sources of the raw data used in
- 307 the analysis have been cited.

308 **References**

- 309 1 WHO. Listings of WHO's response to COVID-19. (2020).
- 310 <<u>https://www.who.int/news/item/29-06-2020-covidtimeline></u>.
- 2 Zhou, P. *et al.* A pneumonia outbreak associated with a new coronavirus of probable
- bat origin. *Nature* **579**, 270-273, doi:10.1038/s41586-020-2012-7 (2020).
- 313 3 Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C. & Garry, R. F. The
- 314 proximal origin of SARS-CoV-2. *Nature Medicine* **26**, 450-452, doi:10.1038/s41591-
- 315 020-0820-9 (2020).
- 316 4 WHO. WHO Coronavirus (COVID-19) dashboard,
- 317 <<u>https://covid19.who.int/region/searo/country/in</u>> (2021).
- 5 Lai, C.-C., Shih, T.-P., Ko, W.-C., Tang, H.-J. & Hsueh, P.-R. J. I. j. o. a. a. Severe
- acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-
- 320 2019 (COVID-19): the epidemic and the challenges. *International Journal of*

- 321 Antimicrobial Agents 55, 105924,
- 322 doi:<u>https://doi.org/10.1016/j.ijantimicag.2020.105924</u> (2020).
- 323 6 Somsen, G. A., van Rijn, C., Kooij, S., Bem, R. A. & Bonn, D. Small droplet aerosols
- 324 in poorly ventilated spaces and SARS-CoV-2 transmission. *The Lancet Respiratory*
- 325 *Medicine* **8**, 658-659, doi:10.1016/S2213-2600(20)30245-9 (2020).
- Johnson, G. *et al.* Modality of human expired aerosol size distributions. *Journal of*
- 327 *Aerosol Science* **42**, 839-851 (2011).
- 328 8 Chen, N. *et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel
- 329 coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet* **395**, 507-
- 330 513, doi:10.1016/S0140-6736(20)30211-7 (2020).
- Wang, D. *et al.* Clinical characteristics of 138 hospitalized patients with 2019 novel
- 332 coronavirus–infected pneumonia in Wuhan, China. *The Journal of American Medical*
- 333 *Association* **323**, 1061-1069, doi:10.1001/jama.2020.1585 (2020).
- Nalbandian, A. *et al.* Post-acute COVID-19 syndrome. *Nature Medicine* 27, 601-615,
 doi:10.1038/s41591-021-01283-z (2021).
- 336 11 Singh, B. B. *et al.* Public health interventions slowed but did not halt the spread of
- 337 COVID-19 in India. *Transboundary and Emerging Diseases* **68**, 2171-2187,
- 338 doi:<u>https://doi.org/10.1111/tbed.13868</u> (2020).
- 339 12 Singh, B. B. *et al.* Meta-analysis and adjusted estimation of COVID-19 case fatality
- risk in India and its association with the underlying comorbidities. *One Health*,
- doi:10.1016/j.onehlt.2021.100283 (2021).
- 34213Pifarré i Arolas, H. et al. Years of life lost to COVID-19 in 81 countries. Scientific
- 343 *Reports* **11**, 3504, doi:10.1038/s41598-021-83040-3 (2021).
- 14 Denny, J., Narassima, M. S., Jaideep, C. M. & Guru Rajesh, J. Estimation of
- economic burden of COVID-19 using disability-adjusted life years (DALYs) and

346 p	roductivity	losses in	Kerala state,	India.	Research So	quare,	doi:10.21203/rs.3.rs-
-------	-------------	-----------	---------------	--------	-------------	--------	-----------------------

- 347 118146/v2 (2021).
- 348 15 MIB. COVID 19 Tracker. Ministry of Information and Broadcasting, Government of
- 349 India., <<u>https://twitter.com/covidnewsbymib/status/1344505201332350977?lang=en</u>>
- 350 (2020).
- 351 16 NCDC. National Centre for Disease Control. COVID-19 Dashboard.,
- 352 <<u>https://ncdc.gov.in/dashboard.php</u>>(2021).
- 17 Indrayan, A., Mishra, A. & Pathak, M. Preliminary Estimates of Years of Life Lost
- 354 (YLL) Due to COVID-19 in India. *medRxiv*, 2020.2010.2024.20218693,
- doi:10.1101/2020.10.24.20218693 (2020).
- 356 18 PIB. Press Information Bureau, Government of India. Updates on COVID-19.
- 357 *Release ID: 1625744.*, <<u>https://pib.gov.in/PressReleasePage.aspx?PRID=1625744</u>>
 358 (2020).
- 359 19 Krishnasamy, N. *et al.* Clinical Outcomes among Asymptomatic or Mildly
- 360 Symptomatic COVID-19 Patients in an Isolation Facility in Chennai, India. *The*
- 361 *American Journal of Tropical Medicine and Hygiene* **104**, 85-90,
- 362 doi:10.4269/ajtmh.20-1096 (2021).
- 363 20 Saurabh, S. *et al.* Tobacco, alcohol use and other risk factors for developing
- 364 symptomatic COVID-19 vs asymptomatic SARS-CoV-2 infection: a case-control
- 365 study from western Rajasthan, India. *Transactions of the Royal Society of Tropical*
- 366 *Medicine and Hygiene* **115**, 820-831, doi:10.1093/trstmh/traa172 (2021).
- 367 21 Soni, S. L. *et al.* Demographic & clinical profile of patients with COVID-19 at a
- tertiary care hospital in north India. *Indian J Med Res* **153**, 115-125,
- 369 doi:10.4103/ijmr.IJMR_2311_20 (2021).

- 370 22 Buitrago-Garcia, D. et al. Occurrence and transmission potential of asymptomatic and
- 371 presymptomatic SARS-CoV-2 infections: A living systematic review and meta-
- analysis. *PLOS Medicine* **17**, e1003346, doi:10.1371/journal.pmed.1003346 (2020).
- 273 23 PIB. Press Information Bureau, Government of India. Home/All Press Release.
- 374 Others. PIB'S daily bulletin on COVID-19.,
- 375 <<u>https://pib.gov.in/PressReleasePage.aspx?PRID=1639305;</u>
- 376 <u>https://pib.gov.in/PressReleasePage.aspx?PRID=1651364</u>> (2020).
- 377 24 Greenhalgh, T., Knight, M., A'Court, C., Buxton, M. & Husain, L. Management of
- 378 post-acute covid-19 in primary care. *BMJ* **370**, m3026, doi:10.1136/bmj.m3026
- 379 (2020).
- 380 25 CSS. COVID symptom study. How long does COVID-19 last? Kings College London,
- 381 2020., <<u>https://covid19.joinzoe.com/post/covid-long-term?fbclid=IwAR1RxIcmmdL-</u>
 382 EFjh_aI-.> (2020).
- 383 26 Moreno-Pérez, O. *et al.* Post-acute COVID-19 syndrome. Incidence and risk factors:
- A Mediterranean cohort study. *J Infect* 82, 378-383, doi:10.1016/j.jinf.2021.01.004
 (2021).
- Logue, J. K. *et al.* Sequelae in Adults at 6 Months After COVID-19 Infection. *JAMA Network Open* 4, e210830-e210830, doi:10.1001/jamanetworkopen.2021.0830
- 388 (2021).
- Wyper, G. M. A. *et al.* Burden of Disease Methods: A Guide to Calculate COVID-19
 Disability-Adjusted Life Years. *Int J Public Health* 66, 1-5,
- doi:10.3389/ijph.2021.619011 (2021).
- Haagsma, J. A. *et al.* Assessing disability weights based on the responses of 30,660
 people from four European countries. *Population Health Metrics* 13, 10,
- doi:10.1186/s12963-015-0042-4 (2015).

395	30	Salomon, J. A. et al. Disability weights for the Global Burden of Disease 2013 study.
396		The Lancet Global Health 3, e712-e723, doi:10.1016/S2214-109X(15)00069-8
397		(2015).
398	31	James, S. L. et al. Global, regional, and national incidence, prevalence, and years
399		lived with disability for 354 diseases and injuries for 195 countries and territories,
400		1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The
401		Lancet 392, 1789-1858, doi:10.1016/S0140-6736(18)32279-7 (2018).
402	32	Kirtana, J. et al. Mild COVID-19 infection-predicting symptomatic phase and
403		outcome: A study from AIIMS, New Delhi. J Family Med Prim Care 9, 5360-5365,
404		doi:10.4103/jfmpc.jfmpc_1610_20 (2020).
405	33	Agarwal, A. et al. Convalescent plasma in the management of moderate covid-19 in
406		adults in India: open label phase II multicentre randomised controlled trial (PLACID
407		Trial). BMJ 371, m3939, doi:10.1136/bmj.m3939 (2020).
408	34	Pannu, A. et al. Severe Acute Respiratory Infection Surveillance during the Initial
409		Phase of the COVID-19 Outbreak in North India: A Comparison of COVID-19 to
410		Other SARI Causes. Indian Journal of Critical Care Medicine 25, 761-767.,
411		doi:10.5005/jp-journals-10071-23882 (2021).
412	35	Daher, A. et al. Clinical course of COVID-19 patients needing supplemental oxygen
413		outside the intensive care unit. Scientific Reports 11, 2256, doi:10.1038/s41598-021-
414		81444-9 (2021).
415	36	Shukla, U., Chavali, S., Mukta, P., Mapari, A. & Vyas, A. Initial Experience of
416		Critically Ill Patients with COVID-19 in Western India: A Case Series. Indian J Crit
417		Care Med 24, 509-513, doi:10.5005/jp-journals-10071-23477 (2020).

- 418 37 Faes, C. *et al.* Time between Symptom Onset, Hospitalisation and Recovery or Death:
- 419 Statistical Analysis of Belgian COVID-19 Patients. Int J Environ Res Public Health
- 420 **17**, 7560, doi:10.3390/ijerph17207560 (2020).
- 421 38 WorldBank. *Population, total India.*,
- 422 <<u>https://data.worldbank.org/indicator/SP.POP.TOTL?locations=IN</u>> (2020).
- 423 39 COI. Census of India 2011. Population enumeration data (Final population),
- 424 <<u>http://censusindia.gov.in/2011census/population_enumeration.html;</u>
- 425 <u>http://censusindia.gov.in/2011-prov-results/indiaatglance.html</u>> (2011).
- 426 40 GBDCN. Global Burden of Disease Collaborative Network. Global Burden of
- 427 Disease Study 2019 (GBD 2019) Reference Life Table. Seattle, United States of
- 428 America: Institute for Health Metrics and Evaluation (IHME).,
- 429 <<u>https://doi.org/10.6069/1D4Y-YQ37</u>> (2021).
- 430 41 IHME. Institute for Health Metrics and Evaluation. Estimation of total mortality due
- 431 to COVID-19., <<u>http://www.healthdata.org/special-analysis/estimation-excess-</u>
- 432 <u>mortality-due-covid-19-and-scalars-reported-covid-19-deaths</u>> (2021).
- 433 42 CIFPC. Confidence Interval For Proportions Calculator. (2021).
- 434 <<u>https://stats.libretexts.org/@go/page/8347</u>>.
- 435 43 Devleesschauwer, B. *et al.* Calculating disability-adjusted life years to quantify
- 436 burden of disease. *International Journal of Public Health* **59**, 565-569,
- 437 doi:10.1007/s00038-014-0552-z (2014).
- 438 44 Devleesschauwer, B. *et al.* DALY calculation in practice: a stepwise approach.
- 439 International Journal of Public Health **59**, 571-574, doi:10.1007/s00038-014-0553-y
- 440 (2014).

- 441 45 Vos, T. *et al.* Global burden of 369 diseases and injuries in 204 countries and
- territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study
- 443 2019. The Lancet **396**, 1204-1222, doi:10.1016/S0140-6736(20)30925-9 (2020).
- 444 46 Menon, G. R. *et al.* National Burden Estimates of healthy life lost in India, 2017: an
- 445 analysis using direct mortality data and indirect disability data. *The Lancet Global*

446 *Health* **7**, e1675-e1684, doi:10.1016/S2214-109X(19)30451-6 (2019).

- 447 47 Wyper, G. *et al.* Inequalities in population health loss by multiple deprivation:
- 448 COVID-19 and pre-pandemic all-cause disability-adjusted life years (DALYs) in
- 449 Scotland. *SocArXiv js3h6*, doi:DOI: 10.31219/osf.io/js3h6 (2021).
- 450 48 Jo, M. W. et al. The Burden of Disease due to COVID-19 in Korea Using Disability-
- 451 Adjusted Life Years. J Korean Med Sci 35, e199-e199,
- 452 doi:10.3346/jkms.2020.35.e199 (2020).
- 453 49 Rommel, A. *et al.* The COVID-19 Disease Burden in Germany in 2020. *Dtsch Arztebl*454 *International* 118, 145-151 (2021).
- 455 50 Quast, T., Andel, R., Gregory, S. & Storch, E. A. Years of life lost associated with
- 456 COVID-19 deaths in the USA during the first year of the pandemic. *Journal of Public*457 *Health*, doi:10.1093/pubmed/fdab123 (2021).
- 458 51 Huang, Q. *et al.* Urban-rural differences in COVID-19 exposures and outcomes in the
- 459 South: A preliminary analysis of South Carolina. *PLoS One* **16**, e0246548,
- 460 doi:10.1371/journal.pone.0246548 (2021).
- 461 52 Kumar, S. *et al.* Who interacts with whom? Social mixing insights from a rural
- 462 population in India. *PLoS One* 13, e0209039, doi:10.1371/journal.pone.0209039
 463 (2018).
- 464 53 Chen, J. *et al.* Effect of modelling slum populations on influenza spread in Delhi.
- 465 *BMJ open* **6**, e011699-e011699, doi:10.1136/bmjopen-2016-011699 (2016).

466 54 Nι	irchis, M.	C. et al. In	pact of the	Burden of CO	OVID-19 in	Italy: Results of
-----------	------------	--------------	-------------	--------------	------------	-------------------

- 467 Disability-Adjusted Life Years (DALYs) and Productivity Loss. *Int J Environ Res*
- 468 *Public Health* **17**, 4233, doi:10.3390/ijerph17124233 (2020).
- 469 55 Oh, I. H. et al. Years of Life Lost Attributable to COVID-19 in High-incidence
- 470 Countries. *J Korean Med Sci* **35**, e300-e300, doi:10.3346/jkms.2020.35.e300 (2020).
- 471 56 Peckham, H. et al. Male sex identified by global COVID-19 meta-analysis as a risk
- 472 factor for death and ITU admission. *Nature Communications* **11**, 6317,
- 473 doi:10.1038/s41467-020-19741-6 (2020).
- 474 57 Zhao, J. et al. Disease Burden Attributable to the First Wave of COVID-19 in China
- and the Effect of Timing on the Cost-Effectiveness of Movement Restriction Policies.
- 476 *Value in Health* **24**, 615-624, doi:10.1016/j.jval.2020.12.009 (2021).
- 477 58 Laxminarayan, R. *et al.* Epidemiology and transmission dynamics of COVID-19 in
 478 two Indian states. *Science* 370, 691, doi:10.1126/science.abd7672 (2020).
- 479 59 Wyper, G. *et al.* Measuring the direct population impact of COVID-19 in Scotland,
- 480 2020: estimating disability-adjusted life years (DALYs) during the first full calendar
- 481 year., doi:10.31235/osf.io/ey36d (2021).
- 482 60 Li, Y. & Nair, H. How reliable are COVID-19 burden estimates for India? *The Lancet*483 *Infectious Diseases*, doi:10.1016/S1473-3099(21)00422-9 (2021).
- 484 61 DHFW. Technical paper COVID 19. Reduction in all-cause mortality in Kerala
- 485 *during COVID-19 pandemic.*, <<u>https://health.kerala.gov.in/pdf/Technical-paper-All-</u>
- 486 <u>Cause-Mortality-Kerala.pdf</u>> (2021).
- 487
- 488
- 489
- 490

	Median YLL	95% UI	Median YLD	95% UI	Median DALY	95% UI
Total	13,992,709	13,958,073-	105,784	50,002-217,970	14,100,422	14,030,129–
		14,027,485				14,213,231
Domain						
Rural	6,102,220	6,087,116-	31,253	14,773-64,397	6,134,167	6,109,995–
		6,117,386				6,168,716
Urban	7,890,488	7,870,957-	74,530	35,229–153,573	7,966,143	7,919,750-
		7,910,099				8,045,000
Gender						
Male	8,955,334	8,933,167-	68,275	32,273-140,681	9,024,833	8,979,611-
	, ,	8,977,590	,	, ,	, ,	9,097,629
Female	5,037,375	5,024,906-	37,508	17,729-77,289	5,075,566	5,050,493-
		5,049,895				5,115,612
	Median	95% UI	Median	95% UI	Median	95% UI
	YLL/100,000		YLD/100,000		DALY/100,000	
	person years		person years		person years	
Total	1,014	1,011-1,016	8	4–16	1,022	1,017-1,030
Domain						
Rural	642	641–644	3	2–7	646	643–649
Urban	1,836	1,831–1,840	17	8–36	1,854	1,842–1,872
Gender						
	1,261	1,258-1,264	10	5-20	1,270	1,264–1,281
Male	1.201					

491 Table 1: Estimated annual disability adjusted life years (DALYs) due to excess COVID-19 deaths in 2020 in India.

492 95% UI = $2.5-97.5^{\text{th}}$ percentile

493 Table 2: Estimated annual disability-adjusted life years (DALYs) due to excess COVID-

	95% UI	Median DALY	95% UI
DALYs		per 100,000	
		person-years	
14,100,422	14,030,129–	1022	1,017–1,030
	14,213,231		
189,636	187,389–194,019	61	61–63
237,600	233,106–246,611	83	81–86
760,728	748,089–785,869	311	306–322
1,485,568	1,472,653–1,509,745	758.4	752–771
2,652,051	2,639,491–2,671,686	1,822	1,814–1,836
3,921,906	3,908,098–3,939,808	4,069	4,055–4,088
3,265,799	3,255,655–3,277,308	5,001	4,986–5,019
1,326,741	1,322,679–1,331,288	5,481	5,464–5,499
245,109	244,293–246,096	3,805	3,793-3,821
15,072	14,996–15,194	714	710-720
	14,100,422 189,636 237,600 760,728 1,485,568 2,652,051 3,921,906 3,265,799 1,326,741 245,109	14,100,42214,030,129-14,213,231189,636187,389-194,019237,600233,106-246,611760,728748,089-785,8691,485,5681,472,653-1,509,7452,652,0512,639,491-2,671,6863,921,9063,908,098-3,939,8083,265,7993,255,655-3,277,3081,326,7411,322,679-1,331,288245,109244,293-246,096	14,100,42214,030,129-102214,213,2311022189,636187,389-194,01961237,600233,106-246,61183237,600233,106-246,61183760,728748,089-785,8693111,485,5681,472,653-1,509,745758.42,652,0512,639,491-2,671,6861,8223,921,9063,908,098-3,939,8084,0693,265,7993,255,655-3,277,3085,0011,326,7411,322,679-1,331,2885,481245,109244,293-246,0963,805

494 **19 deaths in various age groups in 2020 in India.**

495 95% UI = 2.5-97.5th percentile

496

497

498